Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer

Tomkowski, Witold; Filipecki, S

doi:10.1016/s0169-5002(96)00631-9

Cited by 36 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from the literature indicates that prevention of recurrences may be obtained with intrapericardial instillation of classic sclerosing agents, intrapericardial instillation of agents with direct cytotoxic activity against malignant cells, intrapericardial treatment with immunomodulators, systemic antitumor therapy, radiation therapy, or surgical methods [1,4,6,7,9,10,11,12,14,20,21,23,26,27]. Several substances (classic sclerosing agents such as tetracycline, doxycycline, minocycline, and bleomycin) have been investigated for intrapericardial fibrosis (sclerotherapy or sclerosis) that can prevent reaccumulation of malignant effusion [26].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade

Tomkowski¹,

Wı́sniewska

Szturmowicz³

et al. 2004

Supportive Care in Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade

Tomkowski¹,

Wı́sniewska

Szturmowicz³

et al. 2004

Supportive Care in Cancer

View full text Add to dashboard Cite

show abstract

“…Also, the effectiveness of this agent was apparently due to sclerosis with resulting obliteration of the pericardial cavity rather than a direct anti-neoplastic effect [16]. During intrapericardial instillation of cisplatin [3,17], atrial arrhythmias (transient ventricular fibrillation) were observed in 19% of patients and mild nausea as well as pain in 6%. Relatively high rates of response without significant side effects, such as retrosternal pain or changes in ECG, have been described for thiotepa [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Intrapericardial Instillation of Mitoxantrone in Palliative Therapy of Malignant Pericardial Effusion

et al. 2003

View full text Add to dashboard Cite

Background: Pericardial effusions occurring with pericardial or myocardial metastases often cause serious complications, necessitating temporary or emergency relief by percutaneous pericardiocentesis. However, this often results in recurrences. For long-term therapy success, the intrapericardial instillation of anti-neoplastic agents is an alternative to surgical methods, which are stressful for the patient. Following our positive experiences with mitoxantrone in the treatment of malignant pleural effusions, we applied this substance for the therapy of malignant pericardial effusions. Patients and Methods: 16 patients with cytologically verified malignant pericardial effusions (8 with bronchial carcinoma, 7 with carcinoma of the breast, 1 with adenocarcinoma of the stomach) received an intrapericardial instillation of mitoxantrone 1–3 ×10–20 mg. Responses were evaluated by echocardiography 30 days after completion of therapy. Results: 12 of 16 patients showed complete remission (no recurrence of a detectable effusion). 3 patients showed a partial remission (recurrence of non-drainage-dependent effusion) (CR + PR = 94%). Within the mean follow-up period of 189 days no recurrences occurred. The rate of side effects was low. Conclusion: Intrapericardial instillation of mitoxantrone is a feasible and effective palliative method for the control of malignant pericardial effusions with little strain on the patients, short duration of hospital stay, cytotoxic characteristics of the substance with a correspondingly high rate of response and low side effects.

show abstract

“…The total survival of patients ranged from 2 to 24.1 months (the median being 3.7 months, and the average being 6.59 months). Paroxysmal atrial fibrillation was diagnosed in 18.8% patients, and one patient suffered from nausea (24).…”

Section: Management Of the First Episode Of Cardiac Tamponadementioning

confidence: 99%

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis

Darocha¹,

Wilk²,

Walaszkowska-Czyż³

et al. 2018

View full text Add to dashboard Cite

. Conclusion: Efficacy of rescue intrapericardial chemotherapy with cisplatin is independent of parameters of hemodynamic instability and levels of inflammatory markers in recurrent pericardial effusion.Pericardial diseases constitute an infrequent, although very serious clinical problem among oncological patients. They practically always cause deterioration of the patient's quality of life. The increasing amount of pericardial effusion and the resulting cardiac tamponade is a life-threatening condition which requires urgent diagnostics and treatment.The European Society of Cardiology (ESC) Position Paper related to cardio-oncology summarizes the knowledge on acute and chronic pericarditis as the complication resulting from anticancer treatment: some cytotoxic drugs and radiotherapy (1). Experts indicate that pericardial complications in oncology are usually associated with mediastinal tumors occupying the pericardium. The document does not discuss the issue of pericardial effusion as a potential manifestation of malignant tumor progression. The present state of knowledge concerning malignant pericarditis is based on several retrospective studies and descriptions of small groups of patients. This article presents our own prospective experience related to the treatment of patients suffering from recurrent pericardial effusion and hemodynamic instability in the course of malignant disease.The primary purpose of the observation was the assessment of determinants of overall survival of oncological patients subject to emergency pericardiocentesis and intrapericardial chemotherapy with the use of cisplatin due to recurrent symptomatic pericardial effusion and cardiac tamponade.The detailed aims included the identification of factors which could have direct impact on the overall survival of patients, these included among others: complications of pericardiocentesis and cisplatin administered intrapericardially; signs of inflammatory process: pericardial effusion culture test results, fever, white blood cell count; hemodynamic conditions: baseline level of N-terminal pro-B type natriuretic peptide (NTproBNP), volume and duration of pericardial drainage; interval for recurrence pericardial effusion; possibility of further anticancer treatment. 373

show abstract

Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion in the course of the lung cancer

Cited by 36 publications

References 15 publications

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade

Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade

Intrapericardial Instillation of Mitoxantrone in Palliative Therapy of Malignant Pericardial Effusion

Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis

Contact Info

Product

Resources

About